Head-to-head evidence
Eribulin mesylate vs Utidelone
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: Tubulin / microtubules · full HR+/HER2- Metastatic Breast Cancer pipeline
Eribulin mesylate
Marketed by Eisai and partners
NCT00337103 · Phase 3 · completed
Randomized, open-label, active-controlled phase 3 trial of eribulin versus capecitabine in advanced breast cancer, with hard clinical primary endpoints of overall survival and progression-free survival and a large sample size (1102 randomized). It is limited by being open-label, and the posted results give only medians and confidence intervals without p-values or hazard ratios: overall survival trended in favor of eribulin, while progression-free survival trended in favor of capecitabine, so the primary comparison is unclear.
Next expected readout: December 2026 · NCT06202261 (registry estimate)
Utidelone
Developed by Beijing Biostar Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT05398861 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Eribulin mesylate's landscape · Utidelone's landscape